Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.

Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22.

View in: PubMed

subject areas

Administration, Oral
Aged
Aged, 80 and over
Analysis of Variance
Biological Availability
Blotting, Western
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Hematologic Neoplasms
Humans
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Recurrence, Local
Quinolones
Risk Assessment
Salvage Therapy
Statistics, Nonparametric
Survival Analysis
Treatment Outcome

authors with profiles

Richard A. Larson
Mark J. Ratain
Thomas F. Gajewski
Olatoyosi Odenike
Wendy Stock
Theodore Karrison